These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Combined Quantification of Lee H; Nakamoto R; Moore SE; Pantel AR; Eads JR; Aparici CM; Pryma DA Acad Radiol; 2022 Sep; 29(9):1308-1316. PubMed ID: 34836776 [TBL] [Abstract][Full Text] [Related]
6. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of Adnan A; Basu S J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476 [TBL] [Abstract][Full Text] [Related]
7. The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Classification System With Prognostic Impact. Hayes AR; Furtado O'Mahony L; Quigley AM; Gnanasegaran G; Caplin ME; Navalkissoor S; Toumpanakis C Clin Nucl Med; 2022 Jan; 47(1):26-35. PubMed ID: 34874347 [TBL] [Abstract][Full Text] [Related]
8. A prospective head-to-head comparison of Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429 [TBL] [Abstract][Full Text] [Related]
9. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. Hindié E Theranostics; 2017; 7(5):1159-1163. PubMed ID: 28435455 [TBL] [Abstract][Full Text] [Related]
10. Heterogeneous Uptake of 68 Ga-DOTATATE and 18 F-FDG in Initial Diagnosed Neuroendocrine Tumors Patients : Which Patients Are Suitable for Dual-Tracer PET Imaging? Zhou Y; Li L; Wang H; Huang HX; Cao D; Ke NW; Su MG; Tian R Clin Nucl Med; 2024 Jun; 49(6):516-520. PubMed ID: 38637950 [TBL] [Abstract][Full Text] [Related]
11. Clinical and Prognostic Value of PET/CT Imaging with Combination of Zhang P; Yu J; Li J; Shen L; Li N; Zhu H; Zhai S; Zhang Y; Yang Z; Lu M Contrast Media Mol Imaging; 2018; 2018():2340389. PubMed ID: 29681780 [TBL] [Abstract][Full Text] [Related]
12. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215 [TBL] [Abstract][Full Text] [Related]
13. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with Sampathirao N; Basu S J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019 [TBL] [Abstract][Full Text] [Related]
14. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors. Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446 [TBL] [Abstract][Full Text] [Related]
16. Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. Chan DL; Pavlakis N; Schembri GP; Bernard EJ; Hsiao E; Hayes A; Barnes T; Diakos C; Khasraw M; Samra J; Eslick E; Roach PJ; Engel A; Clarke SJ; Bailey DL Theranostics; 2017; 7(5):1149-1158. PubMed ID: 28435454 [No Abstract] [Full Text] [Related]
17. Evaluating Prognosis of Gastrointestinal Metastatic Neuroendocrine Tumors: Constructing a Novel Prognostic Nomogram Based on NETPET Score and Metabolic Parameters from PET/CT Imaging. Liu Y; Cui R; Wang Z; Lin Q; Tang W; Zhang B; Li G; Wang Z Pharmaceuticals (Basel); 2024 Mar; 17(3):. PubMed ID: 38543159 [TBL] [Abstract][Full Text] [Related]
18. Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors. You H; Kandathil A; Beg M; De Blanche L; Kazmi S; Subramaniam RM Nucl Med Commun; 2020 Oct; 41(10):1060-1065. PubMed ID: 32732600 [TBL] [Abstract][Full Text] [Related]
19. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518 [TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor imaging with [ Zhao L; Pang Y; Wang Y; Chen J; Zhuang Y; Zhang J; Zhao L; Sun L; Wu H; Chen X; Lin Q; Chen H Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1360-1373. PubMed ID: 34665275 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]